Neuraxpharm Buccolam Acquisition Opens Up Opportunities
Strikes Deal With Takeda For The Only Buccal Midazolam Approved Across Europe
Neuraxpharm says a deal with Takeda to acquire the only buccal midazolam approved across Europe, Buccolam, not only gives the CNS specialist a strong asset but also offers the opportunity to expand its commercial footprint into the Nordics and Ireland.
